FHTX Stock Summary and Trading Ideas (Foghorn Therapeutics | NASDAQ:FHTX)

Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.

Foghorn Therapeutics trades on the NASDAQ stock market under the symbol FHTX.

As of June 12, 2026, FHTX stock price climbed to $4.18 with 157,389 million shares trading.

FHTX has a beta of 1.74, meaning it tends to be more sensitive to market movements. FHTX has a correlation of 0.11 to the broad based SPY ETF.

FHTX has a market cap of $245.42 million. This is considered a Small Cap stock.

Last quarter Foghorn Therapeutics reported $3 million in Revenue and -$.29 earnings per share. This fell short of revenue expectation by $-5 million and exceeded earnings estimates by $.02.

In the last 3 years, FHTX traded as high as $10.25 and as low as $2.70.

The top ETF exchange traded funds that FHTX belongs to (by Net Assets): VTI, IWM, VXF, IBB, VTWO.

FHTX has underperformed the market in the last year with a price return of -7.9% while the SPY ETF gained +24.1%. FHTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -15.0% and -2.3%, respectively, while the SPY returned +11.6% and -1.9%, respectively.

FHTX support price is $3.86 and resistance is $4.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FHTX shares will trade within this expected range on the day.